12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aranesp darbepoetin alfa: Additional Phase III data

Amgen previously reported that Aranesp missed the 2 composite co-primary endpoints of time to all-cause mortality or cardiovascular morbidity and time to all-cause mortality or chronic renal replacement therapy vs. placebo in the TREAT trial in 4,038 patients; and that patients treated with Aranesp were significantly more likely to have a stroke compared with placebo (see BioCentury, Aug. 31, 2009; Oct. 26, 2009; & Nov. 9, 2009)....

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >